View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 16, 2021updated 19 Apr 2021 10:09am

Ideaya doses first patient in solid tumour treatment trial

Ideaya Biosciences has announced first-patient-in (FPI) in Phase I clinical trial of methionine adenosyltransferase 2a (MAT2A) inhibitor IDE397 for treating methylthioadenosine phosphorylase (MTAP) deletion solid tumours.

Ideaya Biosciences has announced first-patient-in (FPI) in Phase I clinical trial of methionine adenosyltransferase 2a (MAT2A) inhibitor IDE397 for treating methylthioadenosine phosphorylase (MTAP) deletion solid tumours.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Earlier, IDE397 had obtained investigational new drug clearance from the US Food and Drug Administration to commence the Phase I trial in the first quarter of this year.

NEXT Oncology Clinical Research director, founder and CEO Anthony Tolcher said: “We are excited to dose the first patient in the evaluation of IDE397 targeting MAT2A in MTAP deletion patients.

“IDE397 has the potential to be broadly impactful for cancer patients with MTAP deletion, which is prevalent in approximately 15% of solid tumours.”

In a 40-plus MTAP-deletion study, IDE397 showed substantial single-agent anti-tumour activity including tumour regressions in various solid tumour types such as NSCLC, gastric, oesophagal, and bladder.

Apart from IDE397 monotherapy, Ideaya is assessing multiple potential combinations in preclinical models. Several trial sites are being initiated across the country to analyse IDE397 clinically.

For the trial, MTAP-deletion patients will be identified for enrolment using commercially available Next Generation Sequencing platforms, as well as an MTAP-IHC assay developed by Ideaya in partnership with Ventana.

Ideaya Biosciences president and CEO Yujiro Hata said: “Dosing our first patient for IDE397 in our Phase I MTAP-deletion solid tumour trial is a substantial company milestone.

“Ideaya is targeting to advance our next two Synthetic Lethality programmes in PARG and Pol Theta to the development candidate stage in 2021 and advancing our internal pipeline in the MTAP-deletion synthetic lethality space to complement our Phase I MAT2A inhibitor IDE397.”

The company also reported encouraging clinical data from the ongoing Phase I/II trial of darovasertib (IDE196) monotherapy and a binimetinib combination therapy in patients with solid tumours, including metastatic uveal melanoma and skin melanoma.

An overall survival rate of 57% was noted in the second line, third line and heavily pre-treated patients with 95% CI at one year.

Furthermore, 80% of evaluable patients in the skin melanoma cohort had tumour reduction.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena